Genotypic variability of melanoma: A therapeutic challenge;Hypervariabilité génotypique des mélanomes: Un défi thérapeutique

Medecine/Sciences

Volumn 22, Issue 2, 2006, Pages 178-182

  Dalle, Stéphane ^a   Martin Denavit, Tanguy ^a   Thomas, Luc ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

CLINICAL TRIAL; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MELANOMA; RECEPTOR GENE; REVIEW; SOMATIC MUTATION;

EID: 32644451428     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2006222178     Document Type: Review

References (36)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365: 687-701.
2. Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 2003; 22: 3081-6.
3. Nelson MA, Radmacher MD, Simon R, et al. Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases. Cancer Genet Cytogenet 2000; 122: 101-9.
4. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.
5. Bastion BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000; 60: 1968-73.
6. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003; 163: 1765-70.
7. Van Dijk M, Sprenger S, Rombout P, et al. Distinct chromosomal aberrations in sinonasal mucosal melanoma as detected by comparative genomic hybridization. Genes Chromosomes Cancer 2003; 36: 151-8.
8. Chudnovsky X, Adams AE, Robbins PB, et al. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 2005; 37: 745-9.
9. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002; 62: 3200-6.
10. Hoglund M, Gisselsson D, Hansen GB, et al. Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004; 108: 57-65.
11. Balazs M, Adam Z, Treszl A, et al. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 2001; 46: 222-32.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
13. Shinozaki M, Fujimoto A, Norton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004; 10: 1753-7.
14. Sharma A, Trivedi NR, Zimmerman MA, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005; 65: 2412-21.
15. Wellbrock C, Ogilvie L, Medley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004; 64: 2338-42.
16. Laud K, Kannengiesser C, Avril MF, et al. BRAF as a melanoma susceptibility candidate gene? Cancer Res 2003; 63: 3061-5.
17. Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003; 9: 3362-8.
18. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95: 1878-90.
19. Davison JM, Rosenbaum E, Barrett TL, et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 2005; 103: 788-92.
20. Hingorani SR, Jacobetz MA, Robertson GP, et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003; 63: 5198-202.
21. Bollag G, Freeman S, Lyons JF, Post LE. Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 2003; 4: 1436-41.
22. Cruz F, Rubin BP, Wilson D, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003; 63: 5761-6.
23. Schaffer JV, Bolognia JL. The melanocortin-1 receptor: red hair and beyond. Arch Dermatol 2001; 137: 1477-1485.
24. Sturm RA, Teasdale RD, Box NF. Human pigmentation genes: identification, structure and consequences of polymorphic variation. Gene 2001; 277: 49-62.
25. Matichard E, Verpillat P, Meziani R, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 2004; 41: e13.
26. Radhi JM. Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components. J Cutan Med Surg 1999; 5: 293-7.
27. Soto JL, Cabrera CM, Serrano S, Lopez-Nevot MA. Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B. BMC Cancer 2005; 5: 36.
28. Mikhail M, Velazquez E, Shapiro R, et al. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 2005; 11: 5153-7.
29. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64-7.
30. Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol 2001; 137: 1493-6.
31. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-40.
32. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6.
33. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8: 15-21.
34. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003; 3: 559-70.
35. Tsao H, Zhang X, Kwitkiwski K, et al. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000; 136: 1118-22.
36. Gillanders E, Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003; 73: 301-13.